Biblio

Author Title [ Type

] Year

Filters: Author is Girschikofsky, Michael [Clear All Filters]

Journal Article

Nikoloudis A, Neumann IJulia, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, Milanov R, Nocker S, Stiefel O, Strassl I, et al. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis. Vaccines (Basel). 2023;11(10).

Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, et al. Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019:JCO1901406.

Machherndl-Spandl S, Vockenhuber T, Binder M, Weltermann A, Apfalter P, Lass-Flörl C, Girschikofsky M. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Leuk Lymphoma. 2022:1-6.

Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT. Am J Hematol. 2023.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJosef, Zaborsky N, Geisberger R, Catakovic K, Hartmann TNicole, Pleyer L, et al. Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol. 2018.

Lehmberg K, Nichols KE, Henter J-I, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosée P, Weitzman S. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015;100(8):997-1004.